Purpose: We report on the early results of fibrin glue assisted, 3-suture microsurgical vasovasostomy (FGV) technique in humans.
Widely accepted as a safe and reliable method of contraception, vasectomy is used by 40 to 60 million men worldwide. 1 A recent population based study shows that while vasectomy rates have remained stable, the incidence of those seeking reversal has increased. 2 In the United States an estimated 500,00 to 750,000 vasectomies are performed per year and 2% to 6% of these men will eventually request a vasectomy reversal. 3 In the civilian sector reversal rates are influenced by cost, but patients in the military health system incur no out-of-pocket expenses. Hence, demand for this procedure in an equal access, no cost medical system may be much greater. However, due to the small number of urologists that serve the large population of military health care beneficiaries, the waiting time for reversal can be several years.
Microsurgical vasovasostomy, as described by Owen 4 and Silber, 5 is the gold standard with overall patency and pregnancy rates reported by the Vasovasostomy Study Group of 86% and 52%, respectively. 6 While the 2-layer technique has been advocated, it is often tedious, time-consuming, and no difference has been demonstrated compared to a microsurgical 1-layer closure. 6 During the last 2 decades alternative methods of vasal anastomosis have been studied to simplify the procedure and reduce operative time. Fibrin as a tissue adhesive has shown promise in reproductive microsurgery on animal models. Bach et al obtained a 50% patency rate using fibrin glue, various temporary splints and macroscopic technique in rabbits. 7 In a nondelayed vasovasostomy rat model Silverstein and Mellinger found that fibrin glue and 2 transmural sutures placed with microscopic technique yielded a 90% patency rate. 8 A delayed vasovasostomy protocol, which more closely replicates the vasal changes found at the time of reversal, was examined by Weiss and Mellinger in a rat model. 9 They found no statistically significant difference in pregnancy rates between a microscopic 2-layer technique and fibrin glue with 2 transmural sutures. 9 In addition to confirming this finding, Vankemmel et al further showed superior patency rates with 3 transmural sutures compared with 2 sutures when used in fibrin glue delayed vasovasostomy. 10, 11 This study was conducted to determine the feasibility of applying a 3-suture microsurgical vasovasostomy technique using a commercially available fibrin tissue adhesive, Tisseel VH ® , in humans, and to report operative times, patency and pregnancy rates.
METHODS AND MATERIALS
After Institutional Review Board approval, an initial group of 5 patients were entered into the study in a prospective manner. After results from the test group showed acceptable results, an additional 37 patients were enrolled. vasostomy (FGV) . No vasoepididymostomies were performed. The age of the patient and partner, obstructive interval, female fertility status, gross appearance and presence of sperm on microscopic examination of vasal fluid, and operative time were noted. Gross appearance of vasal fluid was deemed favorable when clear or cloudy fluid of thin consistency was demonstrated. Unfavorable fluid was defined as thick, water insoluble and toothpaste-like. These qualitative descriptions were reported independently of intraoperative semen analysis (SA) result. Results of the microscopic examination of vasal fluid were reported as either sperm present or absent. A negative intraoperative SA or unfavorable fluid quality was noted only if results from both vas deferens agreed. Patients were to obtain a SA at 6 weeks, 3, 6, 9 and 12 months postoperatively. Due to the nature of this patient population, 2-thirds of the postoperative semen analyses were done at other laboratories. Pregnancy was also noted.
In terms of surgical technique ( fig. 1 ), after an intravenous first generation cephalosporin was given and general anesthesia administered, the external genitalia was prepared in a standard fashion. Both testicles were delivered from the scrotum in an extravaginal fashion through a 6 to 8 cm midline incision. The vasal defect was identified and the abdominal end of the vas dissected without transecting the perivasal tissue. A stay suture was placed through the serosa of the vas and the vas was transected at a 90-degree angle. A vasogram with methylene blue was performed on the abdominal vas to test for patency. The testicular vas was isolated and transected in a similar manner, and the vasal fluid was examined for consistency and sent to the laboratory for microscopic examination. The ends of the vas were brought into close approximation with a 5-zero polydioxanone suture through the perivasal tissues. The cord was wrapped in saline soaked gauze and the procedure repeated on the contralateral side. The operating microscope was bought into the surgical field and 9-zero nylon sutures were placed in a single layer fashion 120 degrees apart. Both anastomoses were completed before applying the fibrin glue. The glue was prepared according to the manufacturer instruction at the start of the case, and dispensed under and on top of the completed anastomosis. Typically the 5 ml package of fibrin sealant was used to cover both anastomoses. The stay sutures were removed and the testicles returned to their respective hemiscrotum after waiting 3 to 5 minutes. The incision was closed in 2 layers with 3-zero chromic suture and infiltrated with local anesthetic, and a sterile dressing and scrotal support were applied.
RESULTS
The characteristics of the patient population are shown in table 1. A previous microsurgical vasovasostomy failed in 1 patient. Followup data were available for 93% (39 of 42) of the patients and mean followup was 6.2 months (range 1.5 to 12). The numbers of patients who were able to complete 1, 2, 3, 4 and 5 SA were 13 (33%), 13 (33%), 11 (28%), 1 (3%) and 1 (3%), respectively. Mean and median sperm concentrations for the followup SA collected are shown in figure 2.
Mean operative time for FGV was 79.4 minutes (range 50 to 120). The convoluted portion of the vas deferens was involved in 36% (30 of 84 vasal units) of anastomoses. Anastomosis to the convoluted vas bilaterally occurred in 7 patients, of whom followup was available in 6. All 6 of these patients were patent on followup. The overall patency rate for FGV was 85% (33 of 39). Patency rates were grouped according to obstructive interval as reported by the Vasovasostomy Study Group, and are shown in table 2.
When the overall intraoperative SA showed sperm, the patency rate was 96% (27 of 28). The patency rate was 100% (16 of 16) when fluid from both sides showed sperm, and it was 92% (11 of 12) when sperm was present unilaterally. The patency rate decreased to 55% (6 of 11) when the intraoperative SA was negative. In the 6 patients who ultimately proved to be patent, the fluid quality was favorable in 67% (4 of 6) and unfavorable in 33% (2 of 6). Of these patients 5 were less than 10 years from vasectomy and 1 was 12 years after vasectomy. In the remaining 5 patients with negative intraoperative SA who remained azoospermic, the fluid quality FIBRIN GLUE ASSISTED 3-SUTURE VASOVASOSTOMY was favorable in only 20% (1 of 5) and unfavorable in 80% (4 of 5). All of these patients with unfavorable semen quality were more than 10 years from vasectomy. Of 38 patients 12 had bilateral unfavorable vasal fluid. Of the 12 patients 6 had sperm on intraoperative SA, of whom 5 were patent after surgery. Only 2 of the 6 patients with a negative intraoperative SA and unfavorable fluid were patent postoperatively. All the patients with unfavorable fluid characteristics who were patent after surgery were within 10 years of vasectomy except 1 who was 13 years out. All of the patients who were azoospermic were 10 years or more from vasectomy.
Three patients have been separated from partners due to military deployment, 5 patients have either separated or divorced and 1 patient is not actively trying to conceive. Female factor infertility affected an additional 9 partners. Nine pregnancies have been confirmed with average time to conception of 4 months (range 2 to 8) by patients who were 6.4 years (range 2 to 10) from vasectomy.
DISCUSSION
The Vasovasostomy Study Group has described patency and pregnancy rates of 97% and 76%, 88% and 53%, 79% and 44% and 71% and 30% for obstructive intervals of less than 3, 3 to 8, 9 to 14 and 15 years or greater, respectively. Overall an 86% patency rate and a 52% pregnancy rate were reported. 6 A sutured vasal anastomosis using microscopic technique provides optimal results but at the expense of considerable time and effort. Alternative methods of vasal anastomosis have been studied to reduce the complexity of the procedure. Fibrin sealant has been used as an adjunct to reproductive microsurgery in the animal model with good results. To the best of our knowledge, this is the first report of its use in human vasovasostomy.
The principle of fibrin sealing involves the use of coagulation factors to initiate the cascade and effect a fibrin seal, thus stabilizing the anastomosis. Fibrinogen, in the presence of thrombin and calcium, is converted to fibrin monomer. The loose fibrin monomer is then converted to a stable crosslinked fibrin polymer. Aprotinin is added to slow the degradation of the fibrin.
The factors associated with the outcome of FGV are the presence of sperm on intraoperative SA, obstructive interval from vasectomy and gross appearance of vas fluid. The presence of sperm on intraoperative SA in this study was associated with patency. The 1 failure in this subgroup in patient number 31 occurred 11 years after vasectomy, and had unfavorable vasal fluid, but sperm was reported on 1 side. It is unclear whether this represents technical failure or laboratory error as vasal fluid is routinely sent to the laboratory for examination for standardization and to decrease operator bias. Patency rates of patients less than 3 years and 3 to 8 years from vasectomy were good after FGV. The 1 treatment failure in the latter subgroup, patient 1 (table 3), was most likely technical in nature as this was the first patient to undergo FGV. Patients farther out from vasectomy did not have as good a result. The patency rates for the greater than 15 years after vasectomy cohort may be artificially high due to the small number of patients studied. The FGV failures (table 3) were generally greater than 10 years out from vasectomy except for 2 patients, numbers 1 and 15. The patency rate for patients with an obstructed interval of 10 years or less was 93% (28 of 30). Of the 11 patients with a negative intraoperative SA 6 were patent postoperatively, and most were within 10 years of vasectomy. Patients with a negative intraoperative SA and unfavorable fluid quality more likely had a poor result. Likewise, patients who have unfavorable fluid characteristics and were 10 years or greater from vasectomy did poorly with FGV.
Followup of this population is admittedly difficult with long deployments, permanent change of duty stations and noncompliance. Lack of postoperative followup is a weakness of this study and may partially be attributed to the population being observed. Only an average of 2.1 (81 of 39) semen analyses were collected per patient after reversal. Excluding patients deployed, separated/divorced, not actively trying to conceive, and whose partners had female factor infertility, the overall pregnancy rate is 43% (9 of 21). With such small numbers and short followup, it is difficult to determine whether this is meaningful.
Operative time for FGV is much less than the standard 1 or 2-layer microsurgical vasovasostomy, which in our hands takes 2.5 to 3 and 3.5 to 4 hours, respectively. Recently, vasovasostomy in the convoluted vas was shown to be comparable to anastomosis in the straight portion of the vas. 12 The FGV technique is also applicable to anastomoses in the convoluted vas deferens, as our patency rate in this situation is 100% (6 of 6). There have been concerns about the contact of fibrin glue with the vas lumen. We have not experienced any detrimental results with this product, but stress that precise microsurgical apposition is, as has been affirmed in animal studies, essential in this procedure.
Not all patients are good candidates for FGV. The technique may be more effective in those patients who have sperm on intraoperative SA, or a negative intraoperative SA and are 10 years or less from vasectomy with favorable vasal fluid quality. Thus, patients who would be considered for standard microsurgical vasovasostomy may have similar results with FGV. Patients who have a negative intraoperative SA more than 10 years after vasectomy and have unfavorable fluid characteristics should be considered for vasoepididymostomy. Assuming the results of patients 1 and 31 were due to technical factors, 11% (4 of 38) of patients may have achieved patency with vasoepididymostomy.
The fibrin tissue adhesive used in this study is of human (fibrinogen and thrombin) and bovine (aprotinin) origin, and there are concerns about the safety of its use in light of human immunodeficiency virus and bovine spongiform encephalopathy. Although the potential to transmit infectious agents cannot be totally eliminated, the product undergoes vapor heated viral inactivation and no documented cases of hepatitis A, B or C, or HIV transmission, have been ascribed to its use during the last 20 years in a variety of surgical fields. 13 Studies have reported replacing various components of fibrin glue with autologous fibrinogen and aminocaproic acid or tranexamic acid.
14, 15 Recombinant components are available but have not been studied in this type of setting.
CONCLUSIONS
FGV is less time-consuming than standard microsurgical vasovasostomy and may be appropriate for patients with sperm on intraoperative SA or a negative intraoperative SA and an obstructive interval of 10 years or less. Patients without these findings should be considered for vasoepididymostomy. While the early results of FGV are promising, a larger study group with the ability to obtain longer followup is required to definitively establish equivalency to standard microsurgical vasovasostomy.
EDITORIAL COMMENT
This article is the first to my knowledge to describe the use of fibrin glue for vasovasostomy in the human and the authors are to be congratulated. Although the results obtained are reasonable I think that a few caveats must be mentioned. First, because it is not possible to know what type of anastomosis will be required before surgery, the patient must be counseled that if the procedure is being performed by a surgeon who is not facile in vasoepididymostomy, then in the case of epididymal obstruction a vasovasostomy will be performed, which will likely result in a lower patency (and presumably pregnancy) rate. Second, the followup is short and, therefore, the incidence of delayed scarring and obstruction is not known. Finally, based on the patency data, I would recommend this procedure for patients with an obstructive interval of 8 years or less. Although I do not think this technique will replace the standard vasovasostomy, it may represent a viable alternative for the urologist who only performs the occasional vasectomy reversal.
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